Search our Database of Scientific Publications and Authors

I’m looking for a

    303 results match your criteria Cancer Management and Research [Journal]

    1 OF 7

    Standard of care and direct medical costs of the treatment of chronic lymphocytic leukemia among the adult population in Ukraine, Russia, and Kazakhstan: data from the LEUKOSPECT study.
    Cancer Manag Res 2017 7;9:387-395. Epub 2017 Sep 7.
    Novartis Pharma LLC, Moscow, Russia.
    Purpose: The LEUKOSPECT study aimed to describe health service utilization and to estimate the direct medical costs (DMCs) of chronic lymphocytic leukemia (CLL) in 2013 in the adult population of three post-Soviet countries - Russia, Ukraine, and Kazakhstan. As oncologic medical care is provided by federal state-owned, specialized medical institutions, the cost estimation in this study primarily informs from a state budget perspective. Patients' contributions to medical costs were not included in the cost evaluation. Read More

    SIRT1 gene polymorphisms and risk of lung cancer.
    Cancer Manag Res 2017 4;9:381-386. Epub 2017 Sep 4.
    Department of Pathology, Zhejiang Hospital, Hangzhou City, Zhejiang, China.
    Objective: Lung cancer, which is the leading cause of cancer death worldwide, is influenced by a wide variety of environmental and genetic risk factors. The silent information regulator 1 (SIRT1) gene is located on the long arm of chromosome 10 (10q21.3) and has been shown to play crucial roles in lung cancer development in previous studies. Read More

    Treatment and prognostic factors for survival in newly diagnosed multiple myeloma patients with bortezomib and dexamethasone regimen: a single Chinese center retrospective study.
    Cancer Manag Res 2017 24;9:373-380. Epub 2017 Aug 24.
    Department of Hematology and Oncology, Zhongda Hospital, Medical School, Southeast University, Nanjing, People's Republic of China.
    Objective: The aim of this retrospective study was to evaluate the efficacy and prognostic factors of bortezomib and dexamethasone (BD) chemotherapy regimen in the treatment of newly diagnosed multiple myeloma (MM) patients in our hospital.

    Methods: A total of 47 newly diagnosed MM patients treated in our hospital from May 2010 to September 2016 were included in this study. All the enrolled patients received at least two cycles of BD chemotherapy regimen. Read More

    Head and neck cancer: improving outcomes with a multidisciplinary approach.
    Cancer Manag Res 2017 18;9:363-371. Epub 2017 Aug 18.
    Department of Oncology.
    For early-stage head and neck cancer (HNC), surgery (S) or radiotherapy (RT) is a standard treatment. The multidisciplinary approach, which includes multimodality treatment with S followed by RT, with or without chemotherapy (CT) or concurrent chemoradiotherapy (CRT), is required for locally advanced head and neck cancer (LAHNC). CRT improves prognosis, locoregional control (LRC), and organ function in LAHNC, compared to RT alone. Read More

    Vaginal cuff brachytherapy in endometrial cancer - a technically easy treatment?
    Cancer Manag Res 2017 9;9:351-362. Epub 2017 Aug 9.
    Department of Radiation Oncology, Hospital Universitari Sant Joan, Reus, Spain.
    Endometrial cancer (EC) is one of the most common gynecological cancers among women in the developed countries. Vaginal cuff is the main location of relapses after a curative surgical procedure and postoperative radiation therapy have proven to diminish it. Nevertheless, these results have not translated into better survival results. Read More

    Reducing rectal injury in men receiving prostate cancer radiation therapy: current perspectives.
    Cancer Manag Res 2017 28;9:339-350. Epub 2017 Jul 28.
    Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Dose escalation is now the standard of care for the treatment of prostate cancer with radiation therapy. However, the rectum tends to be the dose-limiting structure when treating prostate cancer, given its close proximity. Early and late toxicities can occur when the rectum receives large doses of radiation therapy. Read More

    Survivorship of patients with head and neck cancer receiving care in a tertiary health facility in Nigeria.
    Cancer Manag Res 2017 21;9:331-338. Epub 2017 Jul 21.
    Department of Epidemiology and Medical Statistics, Faculty of Public Health, College of Medicine, University of Ibadan, Ibadan, Oyo State, Nigeria.
    Background: Head and neck cancer (HNC) is a major clinical and public health concern worldwide which impairs the vital functions of life. The treatment of metastatic HNCs is mainly palliative. This study examined the survival patterns and treatment outcomes in patients with HNCs in a tertiary hospital in Nigeria. Read More

    Exploring the acceptability of human papillomavirus self-sampling among Muslim immigrant women.
    Cancer Manag Res 2017 19;9:323-329. Epub 2017 Jul 19.
    University of Michigan Medical School, Ann Arbor, MI, USA.
    Background: With appropriate screening (ie, the Papanicolaou [Pap] test), cervical cancer is highly preventable, and high-income countries, including Canada, have observed significant decreases in cervical cancer mortality. However, certain subgroups, including immigrants from countries with large Muslim populations, experience disparities in cervical cancer screening. Little is known about the acceptability of human papillomavirus (HPV) self-sampling as a screening strategy among Muslim immigrant women in Canada. Read More

    The impact of examined lymph node count on survival in squamous cell carcinoma and adenocarcinoma of the uterine cervix.
    Cancer Manag Res 2017 18;9:315-322. Epub 2017 Jul 18.
    Department of Obstetrics and Gynecology, The First Affiliated Hospital of Xiamen University, Xiamen.
    Introduction: The prognostic impact of the number of examined lymph nodes (ELNs) in different histological subtypes of cervical cancer remains unclear. We aimed to assess the impact of the number of ELNs in stage IA2-IIA cervical cancer with different histological subtypes.

    Methods: Data of patients with stage IA2-IIA squamous cell carcinoma (SCC) and adenocarcinoma (AC) of the uterine cervix between 1988 and 2013 were retrieved from the Surveillance, Epidemiology, and End Results program. Read More

    Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab.
    Cancer Manag Res 2017 12;9:307-314. Epub 2017 Jul 12.
    Department of Pharmaceutical Sciences, School of Pharmacy.
    Treatment options for patients with multiple myeloma (MM) have increased during the past decade. Despite the significant advances, challenges remain on which combination strategies will provide the optimal response for any given patient. Defining optimal combination strategies and corresponding companion diagnostics, that will guide clinical decisions are required to target relapsed or refractory multiple myeloma (RRMM) in order to improve disease progression, survival and quality of life for patients with MM. Read More

    Impact of abiraterone on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives.
    Cancer Manag Res 2017 11;9:299-306. Epub 2017 Jul 11.
    GU Medical Oncology, Inova Schar Cancer Institute, Fairfax, VA, USA.
    Abiraterone acetate has established a major role in the treatment paradigm of metastatic castration-resistant prostate cancer ever since pivotal trials, COU-AA-301 and COU-AA-302, have shown benefit in both the second-line and first-line (post- and pre-chemotherapy) setting, respectively, with improvement in overall survival as well as secondary end points such as prostate-specific antigen (PSA) and radiographic response rates, time to PSA progression, and progression-free survival. There has been a lot of interest and emphasis in the evaluation of patient-related outcomes (PROs) as it relates to quality of life, pain, adverse events, fatigue, and among others, in the use of different agents that have been shown to improve survival. This review examines the companion PROs in conjunction with abiraterone acetate use. Read More

    Induction regimens for transplant-eligible patients with newly diagnosed multiple myeloma: a network meta-analysis of randomized controlled trials.
    Cancer Manag Res 2017 10;9:287-298. Epub 2017 Jul 10.
    Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University.
    Objective: The aim of this study was to compare the early efficacy and survivals of induction regimens for transplant-eligible patients with untreated multiple myeloma.

    Materials And Methods: A comprehensive literature search in electronic databases was conducted for relevant randomized controlled trials (RCTs). Eligible studies were selected according to the predefined selection criteria, before they were evaluated for methodological quality. Read More

    Estrogen-mediated hemangioma-derived stem cells through estrogen receptor-α for infantile hemangioma.
    Cancer Manag Res 2017 7;9:279-286. Epub 2017 Jul 7.
    Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Center for Specialty Strategy Research of Shanghai Jiao Tong University China Hospital Development Institute.
    Background: Infantile hemangiomas (IHs) are the most common benign vascular tumor of infancy. They occur more frequently in female infants. The cause of hemangioma is currently unknown; however, current studies suggested the importance of estrogen (E2) signaling in hemangioma proliferation. Read More

    What we know about surgical therapy in early-stage non-small-cell lung cancer: a guide for the medical oncologist.
    Cancer Manag Res 2017 6;9:267-278. Epub 2017 Jul 6.
    Department of Hematology and Oncology, Staten Island University Hospital - Northwell Health, New York, NY, USA.
    Lung cancer remains the leading cause of death in cancer patients. The gold standard for the treatment of early-stage non-small-cell lung cancer is lobectomy with mediastinal lymph-node dissection or systematic lymph-node sampling. The evidence behind this recommendation is based on the sole randomized controlled trial conducted to date, done by the Lung Cancer Study Group and published in 1995, which found a superiority for lobectomy over sublobar resection with regard to local recurrence rate and improved survival. Read More

    Patient selection for cytoreductive surgery and HIPEC for the treatment of peritoneal metastases from colorectal cancer.
    Cancer Manag Res 2017 30;9:259-266. Epub 2017 Jun 30.
    Department of Surgical Oncology, Catharina Cancer Institute, Eindhoven, The Netherlands.
    Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is a viable option for selected patients with peritoneal metastases (PM) from colorectal origin, resulting in long-term survival and even cure in some cases. However, adequate patient selection for this treatment is currently one of the major challenges. The aim of this review is to provide a comprehensive overview of clinically relevant factors associated with overall survival. Read More

    Tumor cell PD-L1 predicts poor local control for rectal cancer patients following neoadjuvant radiotherapy.
    Cancer Manag Res 2017 29;9:249-258. Epub 2017 Jun 29.
    Department of Radiation Oncology, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou, People's Republic of China.
    The tumor cell (TC) PD-L1 expression has been reported by several studies in various types of cancer, and it reduces the cytotoxicity of T-cells toward cancer and evades the anticancer immune response. Herein, our study focuses on the impact of PD-L1 expression in prognosis and the correlation with clinical prognostic factors for local advanced rectal cancer with neoadjuvant radiotherapy (RT). A total of 68 rectal cancer patients treated with neoadjuvant RT were retrospectively enrolled in the present study. Read More

    Comparison of gefitinib as first- and second-line therapy for advanced lung adenocarcinoma patients with positive exon 21 or 19 del epidermal growth factor receptor mutation.
    Cancer Manag Res 2017 28;9:243-248. Epub 2017 Jun 28.
    Department of Oncology, Zhongda Hospital, Medical School, Southeast University.
    Objectives: Gefitinib, a tyrosine kinase inhibitor (TKI) targeting epidermal growth factor receptor (EGFR), shows excellent clinical benefit in treating advanced non-small-cell lung cancer (NSCLC). The aim of this study was to compare the efficacy and toxicity of gefitinib as first-line therapy and second-line therapy for advanced lung adenocarcinoma patients with positive exon 21 (L858R) or exon 19 deletion of EGFR mutation.

    Methods: We retrospectively analyzed the clinical data of 60 EGFR-mutated advanced lung adenocarcinoma patients from July 2011 to November 2015 who have received oral gefitinib 250 mg once daily. Read More

    Chemotherapy-associated paronychia treated with 2% povidone-iodine: a series of cases.
    Cancer Manag Res 2017 26;9:225-228. Epub 2017 Jun 26.
    Veloce BioPharma LLC, Fort Lauderdale, FL.
    Background: Nail changes are known to occur during the use of chemotherapy for a variety of malignancies, particularly those treated with taxanes and EGFR inhibitors. There are currently no actively recruiting prospective clinical trials investigating potential treatments. There are also no US Food and Drug Administration-approved medical treatments for chemotherapy-associated paronychia and no consensus on the best way to treat these common chemotherapy-induced events. Read More

    Management of malignant pleural effusion: challenges and solutions.
    Cancer Manag Res 2017 23;9:229-241. Epub 2017 Jun 23.
    Oxford Centre for Respiratory Medicine, Respiratory Trials Unit, Oxford University, Oxford, UK.
    Malignant pleural effusion (MPE) is a sign of advanced cancer and is associated with significant symptom burden and mortality. To date, management has been palliative in nature with a focus on draining the pleural space, with therapies aimed at preventing recurrence or providing intermittent drainage through indwelling catheters. Given that patients with MPEs are heterogeneous with respect to their cancer type and response to systemic therapy, functional status, and pleural milieu, response to MPE therapy is also heterogeneous and difficult to predict. Read More

    Emerging use of everolimus in the treatment of neuroendocrine tumors.
    Cancer Manag Res 2017 20;9:215-224. Epub 2017 Jun 20.
    Medical Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain.
    Neuroendocrine tumors (NETs) consist of a diverse family of malignancies, which are derived from neuroendocrine cells, most commonly originating from the gastroenteropancreatic (GEP) tract or the bronchopulmonary system. In general, NETs are more indolent than epithelial tumors, with median survival rates of longer than 30 months. The upregulation of mTOR pathway has been shown to play a pivotal role in NET pathogenesis. Read More

    Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis.
    Cancer Manag Res 2017 14;9:207-213. Epub 2017 Jun 14.
    Developmental Therapeutics Program, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
    Immune checkpoint inhibitors, including cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death-1 (PD-1) inhibitors, represent an effective treatment modality for multiple malignancies. Despite the exciting clinical benefits, checkpoint inhibition is associated with a series of immune-related adverse events (irAEs), many of which can be life-threatening and result in significant treatment delays. Pneumonitis is an adverse event of special interest as it led to treatment-related deaths in early clinical trials. Read More

    Can biosimilars help achieve the goals of US health care reform?
    Cancer Manag Res 2017 1;9:197-205. Epub 2017 Jun 1.
    Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.
    The US Patient Protection and Affordable Care Act (ACA) aims to expand health care coverage, contain costs, and improve health care quality. Accessibility and affordability of innovative biopharmaceuticals are important to the success of the ACA. As it is substantially more difficult to manufacture them compared with small-molecule drugs, many of which have generic alternatives, biologics may increase drug costs. Read More

    Multiple myeloma in Niger Delta, Nigeria: complications and the outcome of palliative interventions.
    Cancer Manag Res 2017 22;9:189-196. Epub 2017 May 22.
    Department of Anatomic Pathology, University of Calabar, Calabar, Nigeria.
    Background: Multiple myeloma (MM) is one of the hematological malignancies that require palliative care. This is because of the life-threatening nature and the suffering associated with the illness. The aim of this study is to bring to the fore the complications experienced by people living with MM in the Niger-Delta region of Nigeria and the outcome of various palliative interventions. Read More

    APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide-based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the Phase III randomized MAGIC trial.
    Cancer Manag Res 2017 19;9:179-187. Epub 2017 May 19.
    Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA.
    Background: APF530, a novel extended-release granisetron injection, was superior to ondansetron in a guideline-recommended three-drug regimen in preventing delayed-phase chemotherapy-induced nausea and vomiting (CINV) among patients receiving highly emetogenic chemotherapy (HEC) in the double-blind Phase III Modified Absorption of Granisetron In the prevention of CINV (MAGIC) trial.

    Patients And Methods: This MAGIC post hoc analysis evaluated CINV prevention efficacy and safety of APF530 versus ondansetron, each with fosaprepitant and dexamethasone, in patient subgroup receiving an anthracycline plus cyclophosphamide (AC) regimen. Patients were randomized 1:1 to APF530 500 mg subcutaneously (granisetron 10 mg) or ondansetron 0. Read More

    Considering renal risk while managing cancer.
    Cancer Manag Res 2017 16;9:167-178. Epub 2017 May 16.
    Medical Oncology Unit, National Cancer Research Centre, Istituto Tumori Giovanni Paolo II, Bari, Italy.
    Renal function is an important consideration in the management of patients with advanced cancer. There is a reciprocal relationship between cancer and the kidney: chronic kidney disease can increase the risk of developing cancer, and patients with cancer often experience renal impairment owing to age, disease-related factors and nephrotoxic treatments. As therapies for cancer continue to improve, patients are living longer with their disease, potentially extending the period over which they are susceptible to long-term complications. Read More

    Oligodendrogliomas in pediatric and adult patients: an outcome-based study from the Surveillance, Epidemiology, and End Result database.
    Cancer Manag Res 2017 2;9:159-166. Epub 2017 May 2.
    Department of Surgery, Saint Barnabas Medical Center, Livingston, NJ, USA.
    Introduction: Oligodendrogliomas (OGs) account for <20% of all intracranial tumors and 25% of gliomas. Despite improvements in imaging techniques allowing for earlier diagnosis, OG is rare among the pediatric population. This study examines a large cohort of OG patients in an effort to define the demographic, clinical, and pathologic factors associated with clinical and survival outcomes. Read More

    Patient and physician preferences for anticancer drugs for the treatment of metastatic colorectal cancer: a discrete-choice experiment.
    Cancer Manag Res 2017 27;9:149-158. Epub 2017 Apr 27.
    Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
    Objective: Many publications describe preferences for colorectal cancer (CRC) screening; however, few studies elicited preferences for anticancer-drug treatment for metastatic CRC (mCRC). This study was designed to elicit preferences and risk tolerance among patients and oncologists in the USA for anticancer drugs to treat mCRC.

    Materials And Methods: Patients aged 18 years or older with a self-reported diagnosis of mCRC and board-certified (or equivalent) oncologists who had treated patients with mCRC were recruited by two survey research companies from existing online patient panels in the USA. Read More

    Rituximab in the treatment of follicular lymphoma: the future of biosimilars in the evolving therapeutic landscape.
    Cancer Manag Res 2017 24;9:131-140. Epub 2017 Apr 24.
    Global Established Pharma, Pfizer Inc., New York, NY, USA.
    Follicular lymphoma (FL) is the second most common type of non-Hodgkin's lymphoma. FL is an incurable disease with treatment options ranging from a "watch-and-wait" approach to localized therapy with radiation or systemic therapy with rituximab in combination with chemotherapy regimens. This review summarizes the role of rituximab across the spectrum of FL treatment and the evolving therapeutic landscape with the emergence of novel agents currently in clinical development. Read More

    Comparative effectiveness and resource utilization of nab-paclitaxel plus gemcitabine vs FOLFIRINOX or gemcitabine for the first-line treatment of metastatic pancreatic adenocarcinoma in a US community setting.
    Cancer Manag Res 2017 21;9:141-148. Epub 2017 Apr 21.
    Celgene Corporation, Summit, NJ.
    Introduction: Despite a clinically relevant, statistically significant survival benefit with nab-paclitaxel plus gemcitabine and FOLFIRINOX vs single-agent gemcitabine for metastatic pancreatic cancer (mPC), little is known regarding their real-world effectiveness. We analyzed patients with mPC using a nationally representative electronic medical records database to address this unmet need.

    Methods: This retrospective analysis of the Navigating Cancer database compared outcomes among patients who received first-line nab-paclitaxel plus gemcitabine, FOLFIRINOX, or gemcitabine for mPC. Read More

    Drainage of malignant ascites: patient selection and perspectives.
    Cancer Manag Res 2017 12;9:115-130. Epub 2017 Apr 12.
    Department of Gynecologic Oncology, Gdynia Oncology Center, Szpitale Wojewodzkie w Gdyni Sp. z o.o., Gdynia, Poland.
    Malignant ascites (MA) is a sign of advanced cancer and poor prognosis. MA can result in impairment in quality of life (QOL) and significant symptoms. As a supportive treatment, ascites can be drained by paracentesis (PC), percutaneously implanted catheters (tunneled, untunneled, central venous catheters), or peritoneal ports, or peritoneovenous shunts. Read More

    The clinical development of obinutuzumab for the treatment of follicular lymphoma.
    Cancer Manag Res 2017 10;9:103-113. Epub 2017 Apr 10.
    Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, DC, USA.
    Impressive progress has been made in recent decades for advanced-stage follicular lymphoma with the availability of anti-CD20 monoclonal antibodies, initially rituximab and more recently obinutuzumab. Obinutuzumab is a unique, third-generation, fully humanized glycoengineered IgG1 type II anti-CD20 monoclonal antibody. It has been shown to have increased antitumor activity compared to rituximab in preclinical studies, including whole-blood B-cell depletion assays, xenograft models, and primate models. Read More

    Symptomatic central nervous system involvement in adult patients with acute myeloid leukemia.
    Cancer Manag Res 2017 29;9:97-102. Epub 2017 Mar 29.
    Hematology, Oncology and Palliative Medicine, Rems-Murr-Klinikum, Winnenden, Germany.
    Introduction: Acute myeloid leukemia (AML) rarely involves the central nervous system (CNS). Little is known about the clinical course in adult AML patients since most studies examined pediatric patients. Therefore, this study analyzed the data of patients treated in three prospective trials of the "Study Alliance Leukemia" (SAL) study group for CNS involvement. Read More

    nab-Paclitaxel for the treatment of pancreatic cancer.
    Cancer Manag Res 2017 16;9:85-96. Epub 2017 Mar 16.
    21st Century Oncology, University of Florida Health Oncology, Jacksonville, FL, USA.
    Background: Nanoparticle albumin-bound paclitaxel (nab-P) plus gemcitabine (Gem) became a standard treatment option for metastatic pancreatic cancer (MPC) following positive results from a global phase III trial (MPACT). A large number of studies have now published results on the use of nab-P/Gem to treat advanced and early-stage disease, warranting a comprehensive review. The main goal of this systematic review is to summarize the efficacy and safety data of nab-P/Gem for the treatment of pancreatic cancer (PC). Read More

    New developments in the management of Waldenström macroglobulinemia.
    Cancer Manag Res 2017 10;9:73-83. Epub 2017 Mar 10.
    Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
    Waldenström macroglobulinemia (WM) is a rare, immunoglobulin M -associated lymphoplasmacytic lymphoma. With the recent discoveries of CXCR warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) and MYD88 mutations, our understanding of the biology of WM has expanded substantially. While WM still remains incurable, the field is rapidly evolving, and a number of promising agents with significant activity in this malignancy are being evaluated currently. Read More

    Glucocorticoid receptor expression in 20 solid tumor types using immunohistochemistry assay.
    Cancer Manag Res 2017 6;9:65-72. Epub 2017 Mar 6.
    QualTek Molecular Laboratories, Newtown, PA.
    Background: Glucocorticoid receptor (GR) activity plays a role in many aspects of human physiology and may play a crucial role in chemotherapy resistance in a wide variety of solid tumors. A novel immunohistochemistry (IHC) based assay has been previously developed and validated in order to assess GR immunoreactivity in triple-negative breast cancer. The current study investigates the standardized use of this validated assay to assess GR expression in a broad range of solid tumor malignancies. Read More

    Update on the optimal use of bortezomib in the treatment of multiple myeloma.
    Cancer Manag Res 2017 2;9:51-63. Epub 2017 Mar 2.
    Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
    The proteasome inhibitor (PI) "bortezomib" has now been in routine clinical practice for over a decade. It is now considered an important backbone therapy for all stages of the disease, and data continue to grow to support its use in newly diagnosed patients, relapsed and relapsed/refractory disease, maintenance therapy, high risk, and renal failure. Much has been learnt about the most clinically effective way of delivering therapy, with patients often benefiting more from a triplet bortezomib combination compared to a doublet combination. Read More

    Differential pharmacology and clinical utility of rolapitant in chemotherapy-induced nausea and vomiting.
    Cancer Manag Res 2017 22;9:41-50. Epub 2017 Feb 22.
    The Medical Oncology Centre of Rosebank, Johannesburg, South Africa.
    Chemotherapy-induced nausea and vomiting (CINV) is a debilitating side effect of many cytotoxic chemotherapy regimens. CINV typically manifests during two well-defined time periods (acute and delayed phases). The acute phase is the first 24 hours after chemotherapy and is largely managed with 5-hydroxytryptamine 3 receptor antagonists. Read More

    Feasibility of an exercise intervention for fatigued breast cancer patients at a community-based cardiac rehabilitation program.
    Cancer Manag Res 2017 10;9:29-39. Epub 2017 Feb 10.
    Department of Medical Oncology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, Canada.
    Purpose: Exercise is beneficial to quality of life after cancer treatment, yet few cancer survivors meet exercise guidelines. Our study sought to determine the feasibility of an oncology rehabilitation exercise program embedded within a cardiac rehabilitation program.

    Methods: Patients who rated their fatigue >4/10 after completion of adjuvant chemotherapy for breast cancer were screened for eligibility and the outcomes were assessed (Piper Fatigue Scale, Functional Assessment of Cancer Therapy-Breast [FACT-B], Edmonton Symptom Assessment System, body composition, stress test, and physical activity measurement [accelerometer]). Read More

    Prospect of the use of checkpoint inhibitors in hepatocellular cancer treatments.
    Cancer Manag Res 2017 9;9:19-27. Epub 2017 Feb 9.
    Division of Hematology/Oncology, Department of Medicine, Joan C. Edwards School of Medicine at Marshall University, Edward Comprehensive Care Center, Huntington, WV, USA.
    Hepatocellular cancer (HCC) is a very fatal disease due to limited therapeutic options as well as due to its association with underlying chronic liver disease in the majority of cases. The immune evasion in HCC signifies a major barrier to the delivery of effective immunotherapy. Sorafenib is the only Food and Drug Administration-approved drug available with an overall response rate of 2%-3% and overall survival of 2. Read More

    Antioxidant activity of ginger extract as a daily supplement in cancer patients receiving adjuvant chemotherapy: a pilot study.
    Cancer Manag Res 2017 31;9:11-18. Epub 2017 Jan 31.
    The College of Pharmacotherapy of Thailand, Nonthaburi; Center for Research and Development of Herbal Health Products; Clinical Pharmacy Division, Faculty of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen, Thailand.
    Purpose: The aim of this study was to examine the antioxidant activity of ginger extract oral supplement in newly diagnosed cancer patients receiving adjuvant chemotherapy compared to placebo.

    Patients And Methods: Newly diagnosed cancer patients receiving moderate-to-high emetogenic potential adjuvant chemotherapy were randomized to receive either a ginger extract (standardized 6-gingerol 20 mg/day) or a placebo 3 days prior to chemotherapy, which they continued daily. Oxidant/antioxidant parameters, including the activities of superoxide dismutase (SOD) and catalase (CAT) and levels of glutathione peroxidase (GPx), total glutathione (GSH/GSSG), lipid peroxidation products detected as malondialdehyde (MDA) and NO2(-)/NO3(-), were measured at baseline and at days 1, 22, 43 and 64 after undergoing chemotherapy. Read More

    Association of fatigue and depression with circulating levels of proinflammatory cytokines and epidermal growth factor receptor ligands: a correlative study of a placebo-controlled fatigue trial.
    Cancer Manag Res 2017 31;9:1-10. Epub 2017 Jan 31.
    The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Context: The biology of fatigue and depression in cancer patients is poorly understood. Hypotheses regarding cytokines and growth factors related to sickness behavior and disruption of circadian signaling have been proposed.

    Objectives: We prospectively examined proinflammatory cytokines (e. Read More

    Implantation of permanent pleural catheter for palliation of malignant pleural effusion.
    Cancer Manag Res 2016 8;8:129-133. Epub 2016 Nov 8.
    Department of Radiology, Aarhus University Hospital, Aarhus, Denmark.
    Purpose: Malignant pleural effusion (MPE) is a disabling condition caused in most instances by far-advanced cancer. The treatment is palliative and should ideally be minimally invasive. The aim of this retrospective study was to evaluate the effectiveness of implantation of a permanent PleurX catheter in the treatment of recurrent MPE in patients with terminal cancer disease. Read More

    Atypical teratoid/rhabdoid tumors: challenges and search for solutions.
    Cancer Manag Res 2016 16;8:115-125. Epub 2016 Sep 16.
    Department of Radiotherapy & Oncology.
    Atypical teratoid/rhabdoid tumor (AT/RT) is a highly malignant embryonal central nervous system tumor commonly affecting children <3 years of age. It roughly constitutes 1%-2% of all pediatric central nervous system tumors. Recent data show that it is the most common malignant central nervous system tumor in children <6 months of age. Read More

    Role of tolvaptan in the management of hyponatremia in patients with lung and other cancers: current data and future perspectives.
    Cancer Manag Res 2016 22;8:105-14. Epub 2016 Aug 22.
    Department of Nephrology, Banner University of Arizona Medical Center; Department of Nephrology, Southern Arizona Veterans Health Care System, Tucson, AZ, USA.
    Hyponatremia is the most frequently observed electrolyte abnormality in clinical practice, and its frequency is almost double in hospitalized cancer patients. As a subset of cancer, hyponatremia is quite common in lung cancer patients, and it is often coupled with the diagnosis of syndrome of inappropriate antidiuretic hormone secretion. The presence of hyponatremia is consequential in that its presence adversely affects cancer patients' prognosis and outcomes. Read More

    Advanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedin.
    Cancer Manag Res 2016 17;8:95-104. Epub 2016 Aug 17.
    Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands; The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK.
    Soft-tissue sarcomas (STS) are a heterogeneous group of rare solid tumors of mesenchymal origin. This paper reviews the current status of systemic treatment in advanced and metastatic soft tissue sarcomas, with an emphasis on trabectedin. Trabectedin is a unique type of chemotherapeutic agent with multiple potential mechanisms of action. Read More

    Treatment challenges for community oncologists treating postmenopausal women with endocrine-resistant, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
    Cancer Manag Res 2016 11;8:85-94. Epub 2016 Jul 11.
    Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
    Community-based oncologists are faced with challenges and opportunities when delivering quality patient care, including high patient volumes and diminished resources; however, there may be the potential to deliver increased patient education and subsequently improve outcomes. This review discusses the treatment of postmenopausal women with endocrine-resistant, hormone receptor-positive, human epidermal growth factor receptor 2- negative advanced breast cancer in order to illustrate considerations in the provision of pertinent quality education in the treatment of these patients and the management of therapy-related adverse events. An overview of endocrine-resistant breast cancer and subsequent treatment challenges is also provided. Read More

    Fosaprepitant dimeglumine for the management of chemotherapy-induced nausea and vomiting: patient selection and perspectives.
    Cancer Manag Res 2016 22;8:77-82. Epub 2016 Jun 22.
    Department of Medicine, Einstein Medical Center, Philadelphia, PA, USA.
    Chemotherapy-induced nausea and vomiting (CINV) is a debilitating side effect of antineoplastic agents. Several treatment regimens are used to address this problem. Fosaprepitant is a neurokinin-1 receptor blocker used in the prevention and treatment of CINV, especially for moderately and severely emetogenic chemotherapy. Read More

    Treatment patterns, health state, and health care resource utilization of patients with radioactive iodine refractory differentiated thyroid cancer.
    Cancer Manag Res 2016 30;8:67-76. Epub 2016 May 30.
    Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR, USA.
    Background: Patients with differentiated thyroid cancer (DTC) often respond well to treatment but some become refractory to radioactive iodine (RAI) treatment, and treatment options are limited. Despite the humanistic and economic burden RAI refractory disease imposes on patients, published research concerning treatment patterns and health care resource utilization is sparse.

    Methods: Data were collected from an online retrospective chart review study in the US and five European Union (EU) countries (France, Germany, Italy, Spain, and UK) with physicians recruited from an online panel. Read More

    1 OF 7